Biotech: Collaboration vs. Competition in Developing Affymax

Gordon Ringold, Surromed

Loading video...

Ringold talks about the decision to move away from being a technology based company at Affymax to applying the technology to pharma because of the relatively small life of a leading technology. Because of lack on internal infrastructure, they decided to sell the company and put it into the hands of a bigger company that had the infrastructure and expertise to use the technology. After a global search, Glaxo bought Affymax, he says.

Feb 26, 2003

More from this event

More on this topic